Health Canada recommends stopping treatment with SGLT2 inhibitors at least three days before surgery or other invasive procedures requiring prolonged fasting.
While the shortage of Ozempic in the U.S. prompts patients and caregivers to turn to compounded products, the Food and Drug Administration is concerned about dosing errors causing overdoses.